Stock Events

Stock Events

Peak Bio 

$0.000500
0
+$0.00+0% Wednesday 16:59

Statistics

Day High
0.0099
Day Low
0.0099
52W High
0.0099
52W Low
0.0099
Volume
10,000
Avg. Volume
-
Mkt Cap
2,687.5
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

26FebExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-0.46
-0.28
-0.1
0.08
Expected EPS
N/A
Actual EPS
N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a leader in mRNA technology, directly competing with Peak Bio's focus on innovative biotechnologies for therapeutics.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the same space as Peak Bio, especially in the development of mRNA-based vaccines and therapies.
Pfizer
PFE
Mkt Cap159.36B
Pfizer collaborates with BioNTech on mRNA vaccines, positioning it as a competitor in the biotech space relevant to Peak Bio's interests.
Novavax
NVAX
Mkt Cap1.53B
Novavax is involved in the development of vaccines for infectious diseases, competing with Peak Bio's therapeutic and vaccine development efforts.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on gene editing, a cutting-edge biotechnology that could compete with Peak Bio's innovative therapeutic approaches.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another company working on CRISPR technology, directly competing with Peak Bio in the gene editing and therapy space.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing sector, making it a competitor to Peak Bio in the pursuit of novel genetic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is engaged in creating transformative medicines for serious diseases, potentially competing with Peak Bio's therapeutic developments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative biologic medicines, competing with Peak Bio in the biopharmaceutical field.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, competing with Peak Bio in the realm of RNA-based therapies.

About

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.
Show more...
CEO
Employees
6
Country
United States
ISIN
US70470P1167

Listings

0 Comments

Share your thoughts

FAQ

What is Peak Bio stock price today?▼
The current price of PKBOW is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Peak Bio stock price performance more closely on the chart.
What is Peak Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Peak Bio stocks are traded under the ticker PKBOW.
What is Peak Bio market cap?▼
Today Peak Bio has the market capitalization of 2,687.5
How many employees does Peak Bio have?▼
As of September 06, 2026, the company has 6 employees.
In which sector is Peak Bio located?▼
Peak Bio operates in the Technology sector.
When did Peak Bio complete a stock split?▼
Peak Bio has not had any recent stock splits.